143 related articles for article (PubMed ID: 37748270)
1. TP53 mutation and abnormal p53 expression in endometrial cancer: Associations with race and outcomes.
Whelan K; Dillon M; Strickland KC; Pothuri B; Bae-Jump V; Borden LE; Thaker PH; Haight P; Arend RC; Ko E; Jackson AL; Corr BR; Ayoola-Adeola M; Wright JD; Podwika S; Smitherman C; Thomas S; Lightfoot M; Newton M; Washington C; Mullen M; Cosgrove C; Harsono AAH; Powell K; Herzog TJ; Salani R; Alvarez Secord A
Gynecol Oncol; 2023 Nov; 178():44-53. PubMed ID: 37748270
[TBL] [Abstract][Full Text] [Related]
2. Impact of age at diagnosis on racial disparities in endometrial cancer patients.
Tarney CM; Tian C; Wang G; Dubil EA; Bateman NW; Chan JK; Elshaikh MA; Cote ML; Schildkraut JM; Shriver CD; Conrads TP; Hamilton CA; Maxwell GL; Darcy KM
Gynecol Oncol; 2018 Apr; 149(1):12-21. PubMed ID: 28800945
[TBL] [Abstract][Full Text] [Related]
3. Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study.
Leslie KK; Filiaci VL; Mallen AR; Thiel KW; Devor EJ; Moxley K; Richardson D; Mutch D; Secord AA; Tewari KS; McDonald ME; Mathews C; Cosgrove C; Dewdney S; Casablanca Y; Jackson A; Rose PG; Zhou X; McHale M; Lankes H; Levine DA; Aghajanian C
Gynecol Oncol; 2021 Apr; 161(1):113-121. PubMed ID: 33541735
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathologic and Genomic Analysis of
Momeni-Boroujeni A; Dahoud W; Vanderbilt CM; Chiang S; Murali R; Rios-Doria EV; Alektiar KM; Aghajanian C; Abu-Rustum NR; Ladanyi M; Ellenson LH; Weigelt B; Soslow RA
Clin Cancer Res; 2021 May; 27(9):2613-2623. PubMed ID: 33602681
[TBL] [Abstract][Full Text] [Related]
5. Racial disparities in molecular subtypes of endometrial cancer.
Dubil EA; Tian C; Wang G; Tarney CM; Bateman NW; Levine DA; Conrads TP; Hamilton CA; Maxwell GL; Darcy KM
Gynecol Oncol; 2018 Apr; 149(1):106-116. PubMed ID: 29605044
[TBL] [Abstract][Full Text] [Related]
6. p53 Immunohistochemical Staining and TP53 Gene Mutations in Endometrial Cancer: Does Null Pattern Correlate With Prognosis?
Sakamoto I; Kagami K; Nozaki T; Hirotsu Y; Amemiya K; Oyama T; Omata M
Am J Surg Pathol; 2023 Oct; 47(10):1144-1150. PubMed ID: 37528644
[TBL] [Abstract][Full Text] [Related]
7.
Thiel KW; Devor EJ; Filiaci VL; Mutch D; Moxley K; Alvarez Secord A; Tewari KS; McDonald ME; Mathews C; Cosgrove C; Dewdney S; Aghajanian C; Samuelson MI; Lankes HA; Soslow RA; Leslie KK
J Clin Oncol; 2022 Oct; 40(28):3289-3300. PubMed ID: 35658479
[TBL] [Abstract][Full Text] [Related]
8. Equivalent Survival of p53 Mutated Endometrial Endometrioid Carcinoma Grade 3 and Endometrial Serous Carcinoma.
Brett MA; Atenafu EG; Singh N; Ghatage P; Clarke BA; Nelson GS; Bernardini MQ; Köbel M
Int J Gynecol Pathol; 2021 Mar; 40(2):116-123. PubMed ID: 32265358
[TBL] [Abstract][Full Text] [Related]
9. Endometrial carcinoma: association between mutational status, sites of metastasis, recurrence, and correlation with overall survival.
Luna C; Goncalves N; Metalonis SW; Mason MM; Lyu J; Huang M; Alessandrino F
Abdom Radiol (NY); 2023 Aug; 48(8):2684-2694. PubMed ID: 37289213
[TBL] [Abstract][Full Text] [Related]
10. Significance of
Chen Y; Zhao W; Bi F; Pan X; Yin L; Zhao C
Oxid Med Cell Longev; 2022; 2022():1817339. PubMed ID: 35847579
[TBL] [Abstract][Full Text] [Related]
11. p53 immunohistochemistry in endometrial cancer: clinical and molecular correlates in the PORTEC-3 trial.
Vermij L; Léon-Castillo A; Singh N; Powell ME; Edmondson RJ; Genestie C; Khaw P; Pyman J; McLachlin CM; Ghatage P; de Boer SM; Nijman HW; Smit VTHBM; Crosbie EJ; Leary A; Creutzberg CL; Horeweg N; Bosse T;
Mod Pathol; 2022 Oct; 35(10):1475-1483. PubMed ID: 35752743
[TBL] [Abstract][Full Text] [Related]
12. CTNNB1 (beta-catenin) mutation identifies low grade, early stage endometrial cancer patients at increased risk of recurrence.
Kurnit KC; Kim GN; Fellman BM; Urbauer DL; Mills GB; Zhang W; Broaddus RR
Mod Pathol; 2017 Jul; 30(7):1032-1041. PubMed ID: 28281553
[TBL] [Abstract][Full Text] [Related]
13. Racial disparities in young women with endometrial cancer.
Mukerji B; Baptiste C; Chen L; Tergas AI; Hou JY; Ananth CV; Neugut AI; Hershman DL; Wright JD
Gynecol Oncol; 2018 Mar; 148(3):527-534. PubMed ID: 29307452
[TBL] [Abstract][Full Text] [Related]
14. Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC).
Labbé C; Cabanero M; Korpanty GJ; Tomasini P; Doherty MK; Mascaux C; Jao K; Pitcher B; Wang R; Pintilie M; Leighl NB; Feld R; Liu G; Bradbury PA; Kamel-Reid S; Tsao MS; Shepherd FA
Lung Cancer; 2017 Sep; 111():23-29. PubMed ID: 28838393
[TBL] [Abstract][Full Text] [Related]
15. Identification of
Beinse G; Rance B; Just PA; Izac B; Letourneur F; Saidu NEB; Chouzenoux S; Nicco C; Goldwasser F; Batteux F; Durdux C; Chapron C; Pasmant E; Leroy K; Alexandre J; Borghese B
Int J Gynecol Cancer; 2020 May; 30(5):640-647. PubMed ID: 32169874
[TBL] [Abstract][Full Text] [Related]
16. The role of racial genetic admixture with endometrial cancer outcomes: An NRG Oncology/Gynecologic Oncology Group study.
Rocconi RP; Lankes HA; Brady WE; Goodfellow PJ; Ramirez NC; Alvarez RD; Creasman W; Fernández JR
Gynecol Oncol; 2016 Feb; 140(2):264-9. PubMed ID: 26603970
[TBL] [Abstract][Full Text] [Related]
17. Effect of race and histology on patterns of failure in women with early stage endometrial cancer treated with high dose rate brachytherapy.
Ozen A; Falchook AD; Varia MA; Gehrig P; Jones EL
Gynecol Oncol; 2015 Aug; 138(2):429-33. PubMed ID: 26024766
[TBL] [Abstract][Full Text] [Related]
18. Race-specific molecular alterations correlate with differential outcomes for black and white endometrioid endometrial cancer patients.
Bateman NW; Dubil EA; Wang G; Hood BL; Oliver JM; Litzi TA; Gist GD; Mitchell DA; Blanton B; Phippen NT; Tian C; Zahn CM; Cohn DE; Havrilesky LJ; Berchuck A; Shriver CD; Darcy KM; Hamilton CA; Conrads TP; Maxwell GL
Cancer; 2017 Oct; 123(20):4004-4012. PubMed ID: 28654152
[TBL] [Abstract][Full Text] [Related]
19. A cost-effective, machine learning-based new unified risk-classification score (NU-CATS) for patients with endometrial cancer.
Zheng S; Wu Y; Donnelly ED; Strauss JB
Gynecol Oncol; 2023 Aug; 175():97-106. PubMed ID: 37336081
[TBL] [Abstract][Full Text] [Related]
20. Mutation spectrum of TP53 gene predicts clinicopathological features and survival of gastric cancer.
Tahara T; Shibata T; Okamoto Y; Yamazaki J; Kawamura T; Horiguchi N; Okubo M; Nakano N; Ishizuka T; Nagasaka M; Nakagawa Y; Ohmiya N
Oncotarget; 2016 Jul; 7(27):42252-60. PubMed ID: 27323394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
